Takeda Collaborates with Carmine for Non-Viral Gene Therapies Worth Up to $900M

Shots:

• The two companies signed a research agreement to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine’s REGENT technology, based on red blood cell extracellular vesicles (RBCEV)
• Carmine to receive upfront, research funding, up to $900M milestones along with royalties on sales of therapies. Following the completion of POC studies, Takeda to get an option to license therapies & will lead development and commercialization activities
• Takeda has committed a $5M convertible loan to support Carmine’s REGENT platform. Carmine unveils that its RBCEV-based gene therapy has the potential for repeat dosing, have large transgene payload capacity more than 11KB with enhanced bio-distribution in selected tissues through RBCEV surface modification

Click here to read full press release/ article | Ref: PRNewswire | Image: Nikkei Asian Review

Related News: Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders